Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News

December 4, 2007 - Patients treated with Abbott Laboratories Inc.’s experimental drug-coated heart stent had low rates ...

Home December 03, 2007
Home
News

December 4, 2007 - In general, drug-eluting stents (DES) achieve better results than bare-metal stents do, U.S ...

Home December 03, 2007
Home
News

December 4, 2007 – American College of Cardiology CEO Jack Lewin has urged ACC members this week to let "their members ...

Home December 03, 2007
Home
News

November 13, 2007 — Arterial Remodeling Technologies (ART) will receive $7.8 million from investors to pursue CE Mark ...

Home November 12, 2007
Home
News

November 4, 2007 – A patient care program in North Carolina shortened the time it took to treat heart attack patients ...

Home November 05, 2007
Home
News

November 4, 2007 - Itamar Medical announced that four presentations at AHA, including one from the Framingham Heart ...

Home November 05, 2007
Home
News

November 5, 2007 - A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER ...

Home November 04, 2007
Home
News

November 5, 2007 – Boston Scientific Corp. highlighted at the American Heart Association conference its new Stentplus ...

Home November 04, 2007
Home
News

November 4, 2007 – The antiplatelet drug prasugrel offered greater benefit than current, standard therapy for patients ...

Home November 03, 2007
Home
News

November 4, 2007 – A specific way of dosing eptifibatide appears equally effective as giving abciximab as an adjunct to ...

Home November 03, 2007
Home
News

November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart ...

Home November 03, 2007
Home
News

October 23, 2007 – Boston Scientific Corp. announced five-year and final follow-up data from its TAXUS IV clinical trial ...

Home October 28, 2007
Home
News

October 24, 2007 - Presented at the TCT 2007 meeting, a pooled analysis of safety data from Medtronic’s ENDEAVOR ...

Home October 24, 2007
Home
News

OCTOBER 23, 2007 – Abbott’s fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease ...

Home October 22, 2007
Home
News

October 23, 2007 - ENDEAVOR IV reached its primary endpoint of target vessel failure non-inferiority when compared to ...

Home October 22, 2007
Home
Subscribe Now